Navigation Links
Cancer 'turns off' important immune cells, complicating experimental vaccine therapies
Date:8/30/2012

Bethesda, MDA research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease. Although problematic for cancer treatment, these flawed dendritic cells could be valuable therapeutic tools for preventing the immune system from attacking what it should not, as is the case with autoimmune disorders and organ transplants.

"Immunotherapy of cancer has been an elusive research target that, though promising, never seems to 'get there,'" said Jos Alexandre M. Barbuto, Ph.D., from the Laboratory of Tumor Immunology, Department of Immunology, Institute of Biomedical Sciences at the University of So Paulo, in So Paulo, Brazil. "This study helps us to better understand the mechanisms by which tumors avoid immune recognition and rejection and may, therefore, teach us how to actually engage effectively the immune system in the fight against tumors, thus achieving much better clinical responses and, consequently, quality of life, in our therapeutic approaches."

To make this discovery, researchers obtained a small sample of blood from breast cancer patients, and from healthy volunteers. The blood cells were then separated and induced to become dendritic cells. Researchers then used these laboratory-generated dendritic cells to induce responses from other immune system cells, namely lymphocytes. While dendritic cells from the healthy donors induced vigorous lymphocytic responses, dendritic cells from cancer patients induced mainly the activation of a specific type of lymphocyte, a regulatory lymphocyte that works as a "brake" for other types of lymphocytes.

"Understanding why the immune system does not recognize and eliminate cancer is critical to developing effective immunotherapies to fight the disease," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Immunologists have been trying to unravel the answer to this question for decades and have realized that the problem is both on the immune system side, and because cancer cells appear to actively 'fly under the radar' avoiding immune system detection. This article offers insights into the underlying mechanisms regulating a key immune cell type, the dendritic cell, involved in initiating anti-tumor responses."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. WSU researchers discover mechanism leading from trichomoniasis to prostate cancer
2. Scientist creates new cancer drug that is 10 times more potent
3. New TGen, Virginia G. Piper Cancer Center study targets non-small cell lung cancer
4. Could a cancer drug potentially prevent learning disabilities in some kids?
5. Aspirin may help men with prostate cancer live longer, study suggests
6. Race May Affect Quality of Prostate Cancer Surgical Care
7. Mayo study: Exercise can help cancer patients, but few oncologists suggest it
8. Exploring exercise benefits for breast cancer patients
9. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
10. Breast Cancer Drug Might Help Men on Prostate Cancer Therapy
11. Reducing the side effects of treatment for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... a 2016-2017 inductee into its VIP Woman of the Year Circle. She is recognized ... organization exclusively for professional women, boasting more than 850,000 members and over 200 operating ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and member ... Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator for ...
(Date:5/3/2016)... ... 2016 , ... California health startup Pegara announced today the ... assess their risk of developing Alzheimer’s disease. Using a questionnaire based on years ... Score™” that summarizes how their lifestyle choices may affect their chances of developing ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... is a process that selects DNA or RNA from a random library of ... potentially be used as drugs or diagnostic agents. SELEX selection is commonly performed ...
(Date:5/3/2016)... Fla. (PRWEB) , ... May 03, 2016 , ... Elizabeth ... her pet parrots to join her with one on her shoulder and one on ... through a parking lot because of years of mitral valve prolapse. , The valves ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
Breaking Medicine Technology: